Patents by Inventor Brett P. Monia

Brett P. Monia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for modulating expression of SGLT2
    Patent number: 8362232
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Modulation of factor 11 expression
    Patent number: 8334372
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 18, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Compositions and their uses directed to acetyl-CoA carboxylases
    Patent number: 8299041
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: October 30, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Brett P. Monia, John G. Geisler, Robert McKay, Kenneth W. Dobie
  • MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION
    Publication number: 20120232125
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 1, such as obesity and obesity-related conditions, are provided.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: BRETT P. MONIA, MARK J. GRAHAM
  • Modulation of diacylglycerol acyltransferase 2 expression
    Patent number: 8258289
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 4, 2012
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Antisense oligonucleotides optimized for kidney targeting
    Patent number: 8258105
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: September 4, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Andrew M. Siwkowski, Edward Wancewicz, Thomas A. Leedom, Lynnetta Watts, Mausumee Guha, Brett P. Monia
  • MODULATION OF FACTOR 7 EXPRESSION
    Publication number: 20120214862
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 7 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: July 15, 2010
    Publication date: August 23, 2012
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
  • COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR
    Publication number: 20120208864
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 16, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • MODULATION OF SGLT-2 EXPRESSION
    Publication number: 20120196921
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Application
    Filed: November 18, 2011
    Publication date: August 2, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts, Thomas A. Leedom
  • ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA
    Publication number: 20120184031
    Abstract: The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Muthiah Manoharan, William A. Gaarde, Richard H. Griffey, Eric E.` Swayze, C. Frank Bennett
  • ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION
    Publication number: 20120149755
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
    Type: Application
    Filed: July 18, 2011
    Publication date: June 14, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Brett P. Monia
  • Compounds and methods for modulating expression of GCGR
    Patent number: 8188059
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: May 29, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN
    Publication number: 20120115930
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 10, 2012
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: BRETT P. MONIA, C. FRANK BENNETT, WILLIAM A. GAARDE, TRISHA LOCKHART, ROBERT MCKAY
  • Modulation of diacylglycerol acyltransferase 1 expression
    Patent number: 8158597
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 1, such as obesity and obesity-related conditions, are provided.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 17, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Mark J. Graham
  • MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI
    Publication number: 20120083522
    Abstract: Disclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI.
    Type: Application
    Filed: April 15, 2010
    Publication date: April 5, 2012
    Applicant: Isis Pharmaceuitcals, inc.
    Inventors: Brett P. Monia, Jeffrey R. Crosby, Robert A. MacLeod, Susan M. Freier
  • ANTISENSE MODULATION OF PTP1B EXPRESSION
    Publication number: 20120077862
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: July 6, 2011
    Publication date: March 29, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • Compounds and methods for modulating expression of PCSK9
    Patent number: 8143230
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 27, 2012
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
  • COMPOSITIONS AND THEIR USES DIRECTED TO DIACYLGLYCEROL ACYLTRANSFERASE 1
    Publication number: 20120029050
    Abstract: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
    Type: Application
    Filed: July 6, 2011
    Publication date: February 2, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Xing-Xian Yu, Sanjay Bhanot, Brett P. Monia
  • Modulation of SGLT2 expression
    Patent number: 8084436
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: December 27, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts
  • Compositions and their uses directed to hepcidin
    Patent number: 8076306
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert McKay